[
    [
        {
            "time": "2018-03-15",
            "original_text": "What Trends Will Drive Long-Term Growth for Opdivo and Eliquis?",
            "features": {
                "keywords": [
                    "Opdivo",
                    "Eliquis",
                    "long-term growth",
                    "trends"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "What Trends Will Drive Long-Term Growth for Opdivo and Eliquis?",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "How Analysts View Approval Delay of Teva’s Migraine Drug",
            "features": {
                "keywords": [
                    "Teva",
                    "migraine drug",
                    "approval delay",
                    "analysts view"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "How Analysts View Approval Delay of Teva’s Migraine Drug",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]